Oxford Nanopore Technologies plc Overview
Pro stress-test →Oxford Nanopore Technologies develops, manufactures, and commercializes DNA/RNA sequencing technology that provides rich data, is fast, accessible, and easy to use, allowing real-time analysis of DNA or RNA. The platform is being developed for the analysis of proteins and metabolites in addition to DNA/RNA sequencing. Its platforms are used in more than 125 countries across healthcare, research, and agriculture.
Strategic Profile
Pro stress-test →FY25 revenue rose 24.2% to £223.9m, with gross margin guidance at approximately 62%. Co-founder Gordon Sanghera departed as chief executive officer, with Francis Van Parys taking over as CEO. The company targets adjusted EBITDA breakeven in FY27, with strong progress in H1 2026.
Competitive Landscape
Pro stress-test →Competitors include Pacific BioSciences, Illumina, OncoDNA, Quantapore, and Vizgen. Oxford Nanopore differentiates through its portable, real-time sequencing platforms and expanding platform breadth across proteins and metabolites. The company competes primarily on speed, accessibility, and platform versatility rather than raw throughput.
Industry Context
Oxford Nanopore Technologies plc operates in Nanopore sequencing.
Key facts
Founded: 2005 · Headquarters: Oxford, United Kingdom · Employees: 1,300 · Revenue: £223.9M for FY2025 (approximately $280M at current rates) · Market cap: $1.57B